Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

18%

2 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 3

1(16.7%)

Phase 4

1(16.7%)

6Total

N/A(4)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT06727474Completed

Clinical and Functional Characteristics of Patients Admitted for Severe COVID-19 Pneumonia

Role: lead

NCT05576246Not ApplicableCompleted

Airway Occlusion Measured During Non-invasive Ventilation to Assess Respiratory Effort

Role: collaborator

NCT05422820Completed

The Argentina Brief Colonoscopy Difficulty Score (ABCD)

Role: collaborator

NCT06109532Unknown

Prevalence of Hyponatremia in Dengue Infected Patients: Relationship With Systemic Inflammation.

Role: lead

NCT05598242Phase 3Completed

Amniotic Membrane Treatment for Hyposecretory Dry Eye

Role: lead

NCT03278639Not ApplicableWithdrawn

Efficacy and Safety or Rhythmic Auditory Stimulation (RAS) for Gait and Balance Disorders in Parkinson's Disease

Role: collaborator

NCT04893928Unknown

Role of Information and Communication Technologies for Health Support in Inflammatory Bowel Diseases: The DAMASCO Trial

Role: lead

NCT04613908Not ApplicableCompleted

Efficacy of Different Treatments for the Intensive Care Unit Acquired Weakness

Role: lead

NCT04493268Completed

HYPONATREMIA IN COVID-19 PATIENTS

Role: lead

NCT04356625Not ApplicableCompleted

Maximum Expiratory Pressure in Induced Cough as a Predictor of Extubation Failure

Role: lead

NCT03608761Phase 4Completed

Comparison Between Rebamipide 2% Versus Autologous Serum

Role: lead

All 11 trials loaded